Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2014

01-09-2014 | Article

Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk

Authors: L. M. Koeth, E. Matuschek, G. Kahlmeter, R. A. Alm, J. E. Ambler

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2014

Login to get access

Abstract

This ceftaroline MIC/disk comparison study for Staphylococcus aureus was performed for the purpose of establishing EUCAST zone diameter breakpoints. Ceftaroline susceptibility for a challenge set of 70 methicillin resistant- and 30 methicillin susceptible-S. aureus was determined by 5-μg disk diffusion and broth microdilution methods. Seventeen isolates were retested by disk and MIC, and the remaining 83 isolates were retested by MIC. Molecular testing was performed on 19 isolates with borderline susceptible ceftaroline MIC results to assess any differences in mecA and epidemiological correlation. An additional set of 101 consecutive clinical S. aureus isolates were tested using the 5-μg disk. S. aureus ATCC 29213 was tested by multiple sites and media for QC range determination. Replicate MIC results were within ±1 doubling dilution, with tendency for slightly lower repeat MICs, and there was minimal variation in replicate zone results. Based on susceptible breakpoints for MIC of ≤1 mcg/mL and for disk of >20 mm, there was 100 % categorical agreement for 30 MSSA and 92 % categorical agreement for 70 MRSA. There were no common MLST or PBP changes for strains with MICs of 1 and 2 mcg/mL. All ceftaroline disk results for the consecutively collected isolates were >20 mm. EUCAST selected the ceftaroline 5-μg disk breakpoint of Susceptible ≥20, Resistant <20 mm because it correlated best with the MIC breakpoint of Susceptible ≤1, Resistant >1 mg/L. A ceftaroline 5-μg disk QC range for S. aureus ATCC 29213 of 24–30 mm was also established by EUCAST.
Appendix
Available only for authorised users
Literature
1.
go back to reference The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. http://www.eucast.org. Accessed 22 Aug 2013 The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. http://​www.​eucast.​org. Accessed 22 Aug 2013
2.
go back to reference Clinical Laboratory and Standards Institute (2013) Performance standards for antimicrobial susceptibility testing, 23rd ed. Approved standard, CLSI publication M100-S23. Clinical Laboratory and Standards Institute, Wayne Clinical Laboratory and Standards Institute (2013) Performance standards for antimicrobial susceptibility testing, 23rd ed. Approved standard, CLSI publication M100-S23. Clinical Laboratory and Standards Institute, Wayne
3.
go back to reference Farrell DJ, Flamm RK, Jones RN, Sader HS (2010) Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe. Diagn Microbiol Infect Dis 2013;75:86–88 Farrell DJ, Flamm RK, Jones RN, Sader HS (2010) Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe. Diagn Microbiol Infect Dis 2013;75:86–88
4.
go back to reference ISO 20776–1 (2006) Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. http://www.iso.org/iso/catalogue_detail.htm?csnumber=41630. Accessed 12 March 2014 ISO 20776–1 (2006) Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. http://​www.​iso.​org/​iso/​catalogue_​detail.​htm?​csnumber=​41630. Accessed 12 March 2014
6.
go back to reference Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K (2012) Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 67(6):1321–1324PubMedCrossRef Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K (2012) Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 67(6):1321–1324PubMedCrossRef
7.
go back to reference Alm R, Lahiri S, Sader HS, Iaconis J (2013) Molecular characterisation of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme. ECCMID O282 Alm R, Lahiri S, Sader HS, Iaconis J (2013) Molecular characterisation of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme. ECCMID O282
Metadata
Title
Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk
Authors
L. M. Koeth
E. Matuschek
G. Kahlmeter
R. A. Alm
J. E. Ambler
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2014
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-014-2089-8

Other articles of this Issue 9/2014

European Journal of Clinical Microbiology & Infectious Diseases 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.